U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H9Cl2F2N3OS
Molecular Weight 436.262
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NEFLAMAPIMOD

SMILES

FC1=CC=C(SC2=NN3C=NC(=O)C(=C3C=C2)C4=C(Cl)C=CC=C4Cl)C(F)=C1

InChI

InChIKey=VEPKQEUBKLEPRA-UHFFFAOYSA-N
InChI=1S/C19H9Cl2F2N3OS/c20-11-2-1-3-12(21)17(11)18-14-5-7-16(25-26(14)9-24-19(18)27)28-15-6-4-10(22)8-13(15)23/h1-9H

HIDE SMILES / InChI
VX-745 (Neflamapimod) is a brain-penetrant highly selective, orally bioavailable drug that inhibits the intracellular enzyme p38 mitogen-activated protein kinase alpha (MAPKa). It is currently in phase 2 clinical studies in patients with early Alzheimer's disease. The targeting of p38 MAPK by VX-745 was associated with the suppression of the release of inflammatory mediators, including interleukin (IL)-1β and tumor necrosis factor (TNF)α, known to be implicated in exacerbating the pathophysiology of rheumatoid arthritis (RA). The drug was in phase II of the clinical trial for RA, but that studies were discontinued.

Approval Year

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >40 uM]
no [IC50 >40 uM]
no [IC50 >40 uM]
no [IC50 >40 uM]
no [IC50 >40 uM]
no
no
no
no
no
yes [IC50 <10 uM]
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30

Sample Use Guides

VX-745 dose level 1 twice daily
Route of Administration: Oral
Cell data for VX-745 in a human peripheral blood mononuclear cell (PBMC) assay provided IC50 values of 56 and 52 nM for IL-1β and TNFα, respectively, and VX-745 blocked IL-6 and IL-8 production induced by IL-1 and TNFα, and cyclooxygenase (COX)-2 synthesis mediated by LPS and IL-1β. In a human whole blood assay, IC50 values were 152 and 177 nM for IL-1β and TNFα inhibition, respectively.
Name Type Language
NEFLAMAPIMOD
INN   USAN  
INN   USAN  
Official Name English
neflamapimod [INN]
Common Name English
NEFLAMAPIMOD [USAN]
Common Name English
6H-PYRIMIDO(1,6-B)PYRIDAZIN-6-ONE, 5-(2,6-DICHLOROPHENYL)-2-((2,4-DIFLUOROPHENYL)THIO)-
Systematic Name English
VX-745
Code English
VRT-031745
Code English
Neflamapimod [WHO-DD]
Common Name English
VD-31,745
Code English
VD-31745
Code English
5-(2,6-DICHLOROPHENYL)-2-((2,4-DIFLUOROPHENYL)THIO)-6H-PYRIMIDO(1,6-B)PYRIDAZINE-6-ONE
Systematic Name English
Code System Code Type Description
SMS_ID
100000183677
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
FDA UNII
TYL52QM320
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
INN
10527
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
PUBCHEM
3038525
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
USAN
CD-175
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
DRUG BANK
DB07138
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
ChEMBL
CHEMBL119385
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
CAS
209410-46-8
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
NCI_THESAURUS
C170207
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID90175115
Created by admin on Fri Dec 15 15:58:51 GMT 2023 , Edited by admin on Fri Dec 15 15:58:51 GMT 2023
PRIMARY